NASDAQ:ZEAL

Zealand Pharma A/S Stock Forecast, Price & News

$29.25
-0.83 (-2.76 %)
(As of 07/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$29.05
$29.74
50-Day Range
$28.30
$32.58
52-Week Range
$27.90
$44.42
Volume2,390 shs
Average Volume15,195 shs
Market Capitalization$1.27 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.18
30 days | 90 days | 365 days | Advanced Chart
Receive ZEAL News and Ratings via Email

Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.


Zealand Pharma A/S logo

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes Dasiglucagon single use syringe or autoinjector that has completed Phase III clinical trials for the treatment of severe hypoglycemia; Dasiglucagon dual-hormone artificial pancreas has completed Phase II clinical trials for automated diabetes management; Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism and in Phase II clinical trials for post bariatric surgery hypoglycemia. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion; and Beta Bionics, Inc. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.33 out of 5 stars

Medical Sector

866th out of 2,215 stocks

Pharmaceutical Preparations Industry

413th out of 867 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Zealand Pharma A/S (NASDAQ:ZEAL) Frequently Asked Questions

Is Zealand Pharma A/S a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zealand Pharma A/S stock.
View analyst ratings for Zealand Pharma A/S
or view top-rated stocks.

What stocks does MarketBeat like better than Zealand Pharma A/S?

Wall Street analysts have given Zealand Pharma A/S a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zealand Pharma A/S wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Zealand Pharma A/S's next earnings date?

Zealand Pharma A/S is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Zealand Pharma A/S
.

How were Zealand Pharma A/S's earnings last quarter?

Zealand Pharma A/S (NASDAQ:ZEAL) released its quarterly earnings data on Tuesday, May, 11th. The company reported ($5.78) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.09) by $4.69. The business had revenue of $7.75 million for the quarter, compared to the consensus estimate of $10.43 million. Zealand Pharma A/S had a negative trailing twelve-month return on equity of 59.47% and a negative net margin of 243.60%.
View Zealand Pharma A/S's earnings history
.

How has Zealand Pharma A/S's stock been impacted by COVID-19 (Coronavirus)?

Zealand Pharma A/S's stock was trading at $28.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ZEAL stock has increased by 4.1% and is now trading at $29.25.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ZEAL?

2 brokerages have issued 12 month target prices for Zealand Pharma A/S's shares. Their forecasts range from $42.00 to $44.00. On average, they anticipate Zealand Pharma A/S's stock price to reach $43.00 in the next year. This suggests a possible upside of 47.0% from the stock's current price.
View analysts' price targets for Zealand Pharma A/S
or view top-rated stocks among Wall Street analysts.

Who are Zealand Pharma A/S's key executives?

Zealand Pharma A/S's management team includes the following people:
  • Dr. Emmanuel Dulac Pharm.D., PharmD, Ph.D., MBA, CEO & Pres (Age 52, Pay $2.03M)
  • Mr. Matthew Donald Dallas, Sr. VP & CFO (Age 46, Pay $924.36k)
  • Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Employee Representative Director (Age 68, Pay $21.68k)
  • Mr. Adam Sinding Steensberg M.D., Exec. VP of R&D and Chief Medical Officer (Age 47, Pay $1.2M)
  • Mr. Ivan Mourits Møller, Sr. VP of Technical Devel. & Operations (Age 49)
  • Ms. Rie Schultz Hansen, VP of Discovery & Innovation
  • Lani Pollworth Morvan, Investor Relations & Communications Officer
  • Mr. Mads Kronborg, Head of Investor Relations & Communication
  • Søren Vitfell Keller, Head of Legal Affairs
  • Mr. Marino Garcia M.B.A., Sr. VP of Corp. & Bus. Devel. (Age 55)

Who are some of Zealand Pharma A/S's key competitors?

What other stocks do shareholders of Zealand Pharma A/S own?

When did Zealand Pharma A/S IPO?

(ZEAL) raised $75 million in an initial public offering on Wednesday, August 9th 2017. The company issued 3,900,000 shares at a price of $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is Zealand Pharma A/S's stock symbol?

Zealand Pharma A/S trades on the NASDAQ under the ticker symbol "ZEAL."

How do I buy shares of Zealand Pharma A/S?

Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zealand Pharma A/S's stock price today?

One share of ZEAL stock can currently be purchased for approximately $29.25.

How much money does Zealand Pharma A/S make?

Zealand Pharma A/S has a market capitalization of $1.27 billion and generates $54.13 million in revenue each year. The company earns $-129,720,000.00 in net income (profit) each year or ($3.38) on an earnings per share basis.

How many employees does Zealand Pharma A/S have?

Zealand Pharma A/S employs 335 workers across the globe.

What is Zealand Pharma A/S's official website?

The official website for Zealand Pharma A/S is www.zealandpharma.com.

Where are Zealand Pharma A/S's headquarters?

Zealand Pharma A/S is headquartered at SYDMARKEN 11, COPENHAGEN G7, 2860.

How can I contact Zealand Pharma A/S?

Zealand Pharma A/S's mailing address is SYDMARKEN 11, COPENHAGEN G7, 2860. The company can be reached via phone at 45-8877-3600 or via email at [email protected]


This page was last updated on 7/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.